



Madrid, July 31, 2024

Making Science Group, S.A. (hereinafter, "Making Science", or the "Company"), pursuant to the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse and Article 228 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity (hereinafter, "BME Growth"), hereby brings to your attention the following information:

### **PRIVILEGED INFORMATION**

In order to offer greater transparency and to provide recurring information to the stock market, the Company wishes to inform the market of the following:

Making Science today announced an agreement whereby the SOPEF II fund (Spain Oman Private Equity Fund), managed by MCH Private Equity, and Making Science Group will finance the growth of its subsidiary Making Science Marketing & AdTech (hereinafter, MSMA) with up to €40 million over the next two years.

Making Science Marketing & AdTech has already received an initial investment from SOPEF II of €5 million and another €2.5 million from its parent company Making Science Group, and for the remainder of 2024, 2025 and 2026, both firms have also agreed to increase their investment to €20 million each (totaling €40 million between them), with the aim of accelerating its international growth in strategic markets for the company. Making Science reserves an option to buy back its stake from SOPEF II beginning in 2027, and SOPEF II has an option to sell its stake beginning in 2028. SOPEF II's future investments (of €15 million) are subject to the execution of a minimum amount of M&A, well below the Company's expected strategy and, moreover, Making Science Group is not obliged to partially or fully carry out future investments; these are subject to the Company's decision. At the time of SOPEF II's entry into the shareholding, its stake is 10.53% of our Business Line MSMA, a business that represents about 65% of Making Science Group's results.

This transaction announced today is part of the growth and international expansion strategy that Making Science has been developing in recent months with the objective set in the guidance ("Plan 2027") presented by the Company. In line with this, at the end of June, the Company successfully closed a capital increase for €4.7 million, an operation that will accelerate the expected growth of the Company's results.

Further details of the transaction will be provided in a conference call or webinar where the CEO will explain the transaction and will be open to all investors, analysts and interested parties, who will be able to follow the presentation online and ask any questions they may have.

### **WEBINAR**

**DATE AND TIME: AUGUST 1, 2024, 9:30 AM**

**WEBINAR REGISTRATION:**

**[https://us02web.zoom.us/webinar/register/WN\\_5\\_h0\\_UWSM-1-DRstwODkw](https://us02web.zoom.us/webinar/register/WN_5_h0_UWSM-1-DRstwODkw)**

In compliance with the provisions of BME MTF Equity Circular 3/2020, it is hereby expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its directors in their current position.

Sincerely yours,

Mr. José Antonio Martínez Aguilar  
Chief Executive Officer of Making Science Group, S.A.